EQS-Adhoc: Cytos Biotechnology AG: Extension of convertible bond listing at SIX Swiss Exchange

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond Cytos Biotechnology AG: Extension of convertible bond listing at SIX Swiss Exchange

2015-04-13 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement.

=--------------------------------------------------------------------

Extension of convertible bond listing at SIX Swiss Exchange

Schlieren (Zurich), Switzerland, April 13, 2015 - Cytos Biotechnology Ltd ("Cytos") today announced that, the last day of trading of the convertible bond at the SIX Swiss Exchange was moved to April 30, 2015. According to the Court the 30 day appeal period related to the bond restructuring was interrupted due to Easter break and therefore has to be formally extended to the end of April.

The final approval of the restructuring by the superior composition authority of creditors of the canton of Zurich ("Obere Kantonale Nachlassbehörde") is expected for the beginning of May 2015, followed by the conversion of the convertible bonds into equity.

For further information, please contact:

Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com End of ad hoc announcement

+++++ Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=JHGGTTLRXU Document title: Cytos_Extension_150413

=--------------------------------------------------------------------

2015-04-13 News transmitted by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

=--------------------------------------------------------------------

Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service =-------------------------------------------------------------------- 343207 2015-04-13 (END) Dow Jones Newswires

   April 13, 2015 01:00 ET (05:00 GMT)- - 01 00 AM EDT 04-13-15